Utah Legislative Recap: February 23, 2024

Funding Requests Life Sciences Initiative – Senator Ann Millner The original initiative requested the legislature provide $7.125M of ongoing funding to higher education in Utah to support the workforce needs of Utah’s Life Sciences industry.  BioUtah has worked closely with Talent Ready Utah, colleges and universities in the state, and other stakeholders to create and […]

Read More

EVŌQ Nano Announces That Its Antimicrobial Medical Device Platform Demonstrates Success Against the Leading Cause of Healthcare-Associated Infections

Novel Nanoparticle Platform Shows Efficacy Against Antimicrobial Resistance; Potential to Disrupt the $29 BillionCatheter Market SALT LAKE CITY, Feb. 22, 2024 /PRNewswire/ — EVŌQ Nano, a nanoscience company that engineers novel nanoparticles for the life, material, and textile science industries, today announced its antimicrobial medical device platform has demonstrated effectiveness against the world’s leading pathogens implicated […]

Read More

Myriad Genetics Appoints Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor of Women’s Health

SALT LAKE CITY, Feb. 15, 2024 (GLOBE NEWSWIRE) — Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the appointment of Dallas Reed, MD, FACOG, FACMG as Principal Medical Advisor to its women’s health business unit, effective immediately. Dr. Reed brings nearly 15 years of clinical and academic experience […]

Read More

Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)

FDA Approval Triggers $225 Million Milestone Payment from Ipsen to Merrimack Merrimack Expects to Hold Special Meeting of Stockholders to Approve Plan of Dissolution in May 2024 Following Approval of Plan of Dissolution, Merrimack Expects to Issue a Liquidating Dividend Currently Estimated to be Between $14.65and $15.35 per Share in the Late Spring or Early […]

Read More

PrecisionLife and Metrodora Institute Partner to Accelerate the Diagnosis and Treatment of Long COVID, ME/CFS, and other Chronic Conditions

Rapid development and clinical validation of diagnostics that enable innovative clinical care pathways in complex, chronic diseases Targeted precision medicine clinical trials leveraging a complementary diagnostic approach are expected to readout results as early as this year   OXFORD, UK and SALT LAKE CITY, US – 15 February 2024 – The pioneering precision medicine company, […]

Read More

Halia Therapeutics Initiates Phase II Clinical Trial to Evaluate Efficacy of HT-6184, a First-in-Class NEK7/NLRP3 Inhibitor, on Post Procedural Inflammatory and Pain Responses

The first patient undergoing wisdom tooth extraction has been dosed with HT-6184 to evaluate its effect on post-procedure diagnostic biomarkers of inflammation and pain, as well as to evaluate its safety and tolerability. LEHI, Utah, Feb. 15, 2024 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, […]

Read More

Merit Medical Receives FDA 510(k) Clearance for SCOUT® MD™ Surgical Guidance System

New guidance system marks significant advancement in breast cancer care, targeting tumor location in multiple dimensions for precise excision and successful surgeries SOUTH JORDAN, Utah, Feb. 15, 2024 (GLOBE NEWSWIRE) — Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, has received US Food and Drug Administration (FDA) 501(k) clearance for the […]

Read More

Centers for Medicare & Medicaid Services Publishes Draft Local Coverage Determination for KidneyIntelX and kidneyintelX.dkd

Posted on

LONDON and SALT LAKE CITY, February 9, 2024 – Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that on February 8, 2024 the Centers for Medicare and Medicaid Services (“CMS”) published a draft Local Coverage Determination (“LCD”) for the Company’s KidneyIntelX and kidneyintelX.dkd testing. The draft LCD can be accessed at https://www.cms.gov/medicare-coverage-database/. The established Medicare price […]

Read More

Utah Legislative Recap, Feb. 9, 2024

Posted on

Funding Requests   Life Sciences Initiative – Senator Ann Millner The original initiative requested the legislature provide $7.125M of ongoing funding to higher education in Utah to support the workforce needs of Utah’s Life Sciences industry.  BioUtah has worked closely with Talent Ready Utah, colleges and universities in the state, and other stakeholders to create […]

Read More

2024 Life Sciences Day on the Hill Recap

Utah’s vibrant life sciences industry was on full display February 7 as part of BioUtah’s “Life Sciences Day on the Hill”. The event, a collarboration with the Governor’s Office of Economic Opportunity, (GOEO) was held at the state capitol. 29 companies exhibited their innovative technologies in the capitol rotunda, which provided legislators the opportunity to […]

Read More

Halia Therapeutics Announces $30M Series C Financing to Advance Novel Pipeline of Anti-Inflammatory Therapeutics

Posted on

Funds will support the advancement of lead programs in Phase II clinical trials, evaluating HT-6184, Halia’s first-in-class NLRP3/NEK7 inflammasome inhibitor, and advancing additional programs into the clinic. LEHI, Utah, Jan. 31, 2024 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, today announced the completion […]

Read More

Halia Therapeutics Dosed its First Patient in Phase 2a Clinical Trial of HT-6184, a First-in-Class NLRP3-Inhibitor, for the Treatment of Lower-Risk Myelodysplastic Syndromes

LEHI, Utah /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, today announced the dosing of the first patient in Phase 2a clinical trial evaluating its lead candidate, HT-6184, for the treatment of lower-risk myelodysplastic syndromes (LR-MDS). HT-6184 is a selective and orally bioavailable first-in-class […]

Read More